化合物RP-6306 T60889

Product Introduction
Bioactivity


英文名: RP-6306

描述: RP-6306 是有效的、选择性的、口服活性的 PKMYT1 抑制剂 (IC50= 14 nM)。RP-6306 在细胞结合测定中显示出比其他激酶更高的选择性。RP-6306 显示出抗癌活性。

体外活性: RP-6306 (500 nM; 24h) treatment induced pan-γH2AX in HCC1569 breast cancer cell line indicates that tumor derived CCNE1 amplification also makes cells susceptible to DNA damage induction after PKMYT1 inhibition. RP-6306 treatment can selectively and accidentally activate CDK1 in CCNE1 overexpression cells, thus promoting early mitosis of cells undergoing DNA synthesis [2].

体内活性: 在经CCNE1放大的卵巢异种移植模型（OVCAR3）中，RP-6306（15、50和300 ppm；口服；每日；持续21天）显著按剂量依赖的方式减少了OVCAR3中的肿瘤生长[1]。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 45.0 mg/mL (138.7 mM)


关键字: RP 6306 | RP6306 | RP-6306

相关产品: ZNL 02-096 | ZN-c3 | WEE1-IN-3 | GSK-1520489A | PD 407824 | Adavosertib | Debio-0123 | PD0166285

相关库: Drug Repurposing Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Clinical Compound Library | Bioactive Compounds Library Max | Kinase Inhibitor Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Active Compound Library | Bioactive Compound Library

化合物RP-6306 T60889信息由TargetMol中国为您提供，如您想了解更多关于化合物RP-6306 T60889报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途